CharleneMarieFaresMD

PubMed

• Homologous recombination deficiency and molecular subtype are associated with immunogenicity in ovarian cancer.
  Charlene M Fares, Kathleen E Fenerty, Cinthiya Chander, Matthew K Theisen, Gottfried E Konecny> ;Biomarkers in Medicine. 2022 Jul 1
• 6 citations
  Immune checkpoint inhibitor induced thyroid dysfunction is a frequent event post-treatment in NSCLC.
  Nanruoyi Zhou, Maria A. Velez, Benjamin Bachrach, Jaklin Gukasyan, Charlene M. Fares, Amy L. Cummings, Jackson P. Lind-Lebuffe, Wisdom O. Akingbemi, Debory Y. Li, Paig...> ;Lung Cancer. 2021 Aug 30
• 4 citations
  Osimertinib as neoadjuvant therapy in a patient with stage IIIA non-small cell lung cancer: a case report
  Caroline Y. Chen, Charlene M. Fares, Daniel Sanghoon Shin> ;Journal of Medical Case Reports. 2021 Apr 24
• 17 citations
  Mutational landscape influences immunotherapy outcomes among patients with non-small-cell lung cancer with human leukocyte antigen supertype B44
  Amy L. Cummings, Jaklin Gukasyan, Henry Lu, Tristan Grogan, Gemalene Sunga, Charlene M. Fares, Nicholas Hornstein, Jesse M. Zaretsky, James M. Carroll, Benjamin Bachra...> ;Nature Cancer. 2020 Nov 16
• 12 citations
  Association of PD-L1 expression by immunohistochemistry and gene microarray with molecular subtypes of ovarian tumors
  Curtis D Chin, Charlene M. Fares, Maira P. Campos, Hsiao-Wang Chen, I. P. Shintaku, Gottfried E. Konecny, Jianyu Rao> ;Modern Pathology. 2020 May 13
• 8 citations
  Biomarkers that may predict response to immunotherapy in ovarian malignancies.
  Curtis D Chin, Charlene M. Fares, Gottfried E. Konecny, Jianyu Rao> ;Current Opinion in Obstetrics & Gynecology. 2020 Feb 1
• 392 citations
  Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?
  Charlene M. Fares, Eliezer M. Van Allen, Charles G. Drake, James P. Allison, Siwen Hu-Lieskovan> ;American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting. 2019 May 17
• 9 citations
  Low Concordance of Patient-Reported Outcomes With Clinical and Clinical Trial Documentation
  Charlene M. Fares, Timothy Williamson, Matthew K. Theisen, Amy L. Cummings, James M. Carroll, Annette L. Stanton, Edward B. Garon, Krikor Bornazyan, Marshall L. Spiegel> ;JCO Clinical Cancer Informatics. 2018 Nov 16
• Join now to see all

Journal Articles

• Mutational landscape influences immunotherapy outcomes among patients with non-small-cell lung cancer with human leukocyte antigen supertype B44  
  Amy L. Cummings, Jaklin Gukasyan, Henry Y. Lu, Tristan Grogan, Gemalene Sunga, Charlene M. Fares, Nicholas Hornstein, Jesse Zaretsky, James Carroll, Benjamin Bachrach,..., Nature Cancer, 11/16/2020